Full Press Release Details
Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra Ahead
of Schedule, and Provides Strategic & Business Updates
Nes-Ziona, Israel, April
29, 2022 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq:
ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced its full year 2021
financial results, the completion of development of a frozen formulation of Allocetra twelve months ahead of schedule, and provided
strategic updates on its clinical programs.
Frozen Formulation of Allocetra Completed Twelve Months Ahead
Development of a frozen formulation Allocetra , a cornerstone
of Enlivex's recent R&D efforts, was completed in Q1 2022, twelve months ahead of Enlivex's schedule. While the liquid
formulation of Allocetra has a shelf life of 96 hours, the frozen formulation is expected to have a shelf life spanning multiple
years. This is expected to substantially improve the product candidate's scalability and shipping logistics, lower its production
costs, and increase profitability upon potential commercialization. Due to the early completion of the development of frozen formulation
Allocetra , Enlivex intends to utilize it in its ongoing Phase II sepsis trial going forward, rather than introducing it only at
the start of a Phase III study. In addition, Enlivex plans to utilize the frozen formulation of Allocetra in its upcoming solid
tumor trials that are expected to begin in late 2022 and onwards and in all subsequent clinical studies moving forward. Use of frozen
formulation Allocetra in clinical trials is subject to the approval of the relevant regulatory authorities.
Sepsis: Integrating Frozen Formulation Allocetra into Phase
II Trial, Expanding Study Population
initiated a placebo-controlled, randomized, dose-finding, multi-center, Phase II trial evaluating liquid Allocetra in patients
with pneumonia-associated sepsis. The Company is now working to amend the protocol of this clinical trial to treat newly recruited patients
with frozen formulation Allocetra and expand the study population to include patients whose septic condition stems from biliary,
urinary tract, or peritoneal infections. Enlivex expects to submit the proposed protocol amendments to regulators in Q2 2022. Due to the
anticipated time needed by regulators to review and approve these amendments, this is expected to briefly defer completion of the trial
by approximately six to eight months, but Enlivex expects that it will significantly shorten the overall timeline for a potential regulatory
approval of frozen formulation Allocetra in sepsis and the associated commercial launch.
Enlivex's Phase II sepsis trial is supported by previously reported
positive results from a Phase Ib trial that demonstrated Allocetra's favorable safety profile and showed vastly improved clinical
outcomes, including SOFA (sequential organ failure assessment) scores, duration of hospitalization, and mortality, in Allocetra-treated
sepsis patients compared to a group of matched historical controls who received standard-of-care therapy. Sepsis is a life-threatening
disease with no FDA approved therapies and a high unmet need. Each year, more than 1.7 million adults in the United States develop sepsis,
with more than 270,000 dying of the disease.
COVID-19 De-Prioritization:
Due to (a) the emergence of variants that may be associated with less
severe disease, (b) a more stringent regulatory environment, and (c) increased volatility of the potential business segment, Enlivex is
de-prioritizing Allocetra's clinical development in COVID-19 and re-allocating the program's cash resources to the Company's
primary development priorities, sepsis and oncology.
Though Enlivex commenced its ongoing Phase IIb COVID-19 trial just
prior to the Omicron-driven surge in COVID-19 infections, the majority of Omicron-infected severe/critical patients were not eligible
for recruitment into the trial, either because COVID-19 was not the reason for their severe/critical condition (i.e., while they had COVID-19,
they were in severe or critical condition for reasons that were not necessarily because of COVID-19), or because they had significant
co-morbidities (e.g., renal insufficiency, cancer) that were the drivers of their condition. Those patients that did meet the trial's
inclusion criteria (age < 90, no significant co-morbidities, severe/critical condition driven by COVID-19) were found to be overwhelmingly
unvaccinated against COVID-19 and unwilling to participate in a clinical trial of an investigational drug candidate. In conjunction with
the decision to de-prioritize its COVID-19 program, the Company plans to cease recruitment of patients into the Phase II trial. Given
the slow recruitment, the total patients enrolled in the trial (11, of which 8 were recruited into the placebo arm) has not been sufficient
to make any meaningful assessments of Allocetra's efficacy. Patients already enrolled in Enlivex's Phase IIb COVID-19 trial
will continued to be followed for assessments of safety.
Solid Tumors: Planned Clinical Trials Evaluating Allocetra
in Patients with Solid Tumors in 2022
A major shortcoming of immunotherapeutic cancer treatments is limited
efficacy against solid tumors, which represent approximately 90% of all cancer cases. Enlivex believes that this is due in large part
to the negative reprogramming of macrophages in the tumor microenvironment, which results in the proliferation of pro-tumor macrophages
that contribute to drug resistance, prevent disease resolution, and promote disease severity. Previously reported preclinical data from
solid tumor models suggest that Allocetra has the potential to reprogram pro-tumor macrophages back to their homeostatic state,
and thereby may promote disease resolution and provide patients that do not respond well to existing FDA-approved immunotherapies with
an effective treatment option. Based on these and other data, Enlivex plans to initiate a Phase Ib trial evaluating Allocetra in
combination with chemotherapy in solid peritoneal tumors in Q3 2022, (one quarter deferral from previous expectations), and a Phase I/II
trial evaluating Allocetra in combination with an immune checkpoint inhibitor in late 2022.
Manufacturing: Positive Regulatory Interaction, Buildup of Plant
& Supply Chain Infrastructure On Schedule
Construction of Enlivex's new cGMP Allocetra manufacturing
plant in Israel has continued to proceed as planned following a positive interaction with regulators. The facility will initially be approximately
17,000 square feet, and will have the ability to be expanded to approximately 21,500 square feet in the future. Additional manufacturing
capacity provided by the facility is intended to support ongoing clinical trials, future clinical trials, and initial commercial production
of Allocetra that may occur if it receives applicable regulatory approvals. The Company's efforts to establish supply
chain infrastructure to support potential commercialization in the future are also advancing on-schedule.
Corporate: Extend Expected Cash Runway to Q3 2024
Enlivex currently expects that its re-prioritization of resources from
COVID-19 to its sepsis, oncology, and manufacturing programs will have extended its cash runway by approximately three quarters. The Company
expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund its operating expenses into Q3 2024.
"Planned amendments to our sepsis trial are expected to accelerate
the program's projected timeline to regulatory approval while expanding its commercial opportunity and potential therapeutic impact,"
said Oren Hershkovitz, Ph.D., CEO of Enlivex. "In addition to broadening the trial to include patients with sepsis stemming from
biliary, urinary tract, or peritoneal infections, we are planning to utilize Allocetra's frozen formulation in the study. Given
this formulation's prolonged shelf-life, we expect its use to dramatically reduce our future manufacturing costs and enable the
geographic expansion of our clinical programs."
continued, "We have also made the decision to de-prioritize Allocetra's development in COVID-19. Effective treatments for
patients with mild-to-moderate disease have proven to be powerful tools that have reduced the need for therapies designed for those in
severe or critical condition. In addition, the recent emergence of variants that may be associated with less severe disease and
a more stringent regulatory environment have collectively led to a sharp increase in the volatility of this potential business segment.
We thus will be focusing our resources on our sepsis and oncology programs. This is expected to extend our cash runway into Q3 2024 and
leave us better positioned to execute on our stated clinical objectives."
Full Year 2021 Financial Results:
Research and development expenses were $12.8 million for the year ended
December 31, 2021, as compared to $6.0 million for 2020. This increase was primarily attributable to increases in salaries, expenses for
preclinical studies and R&D activities, clinical studies and consumption of materials and stock-based compensation to employees and
General and administrative expenses were $6.4 million for the year
ended December 31, 2021, as compared to $ 3.7 million for 2020. This increase was primarily attributable to increases in stock-based compensation
to employees and directors and insurance expenses Net loss for the year ended December 31, 2021 was $14.4 million, as compared to a net
loss of $11.8 million for the year ended December 31, 2020.
of December 31, 2021, Enlivex had cash, cash equivalents, short
term deposits , and marketable securities of $84.1 million.
Allocetra is being developed as a universal, off-the-shelf
cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram
macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective
diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism
of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in
combination with leading therapeutic agents.
Enlivex is a clinical stage macrophage reprogramming